FindTrial
Sign In

Effect of Dapagliflozin on muscle parameters in elderly patients with diabetes mellitus

Effect of SGLT2 inhibitor Dapagliflozin on muscle strength and function in elderly patients with diabetes mellitus - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/04/084686
Enrollment
30
Registered
2025-04-13
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E46- Unspecified protein-calorie malnutrition

Interventions

Intervention1: Oral Dapagliflozin tablet: Baseline muscle parameters will be noted. 10mg od oral tablet Dapagliflozin shall be introduced as a standard of care therapy to patients with diabetes as per

Sponsors

Nitte University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients with type 2 diabetes with age above 60 years irrespective of diabetes duration and HbA1C below 8

Exclusion criteria

Exclusion criteria: Already on SGLT2 inhibitors or insulin therapy,Established CKD/CVA/CAD/CLD,Immobility/restricted mobility due to any reason, Intake of drugs -steroids including anabolic ones, oestrogen, testosterone.

Design outcomes

Primary

MeasureTime frame
Change in muscle strength and muscle functionTimepoint: Following oral dapagliflozin 10mg therapy for 8 weeks—

Secondary

MeasureTime frame
Effect of Glycemic change with dapagliflozin and its effect on muscle strength and muscle functionTimepoint: change over 8 weeks—

Countries

India

Contacts

Public ContactDr VK Sashindran

K.S.Hegde Medical College

vksashindran@gmail.com9958826493

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026